Hastings David C
SEC-identified person · CIK 1237401 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Scynexis INC SCYX | Director | filed 2015 - 2026 |
| Trevi Therapeutics, Inc. TRVI | Chief Financial Officer | filed 2026 - 2026 |
| Tekmira Pharmaceuticals Corp TKMR | Chief Financial Officer | filed 2018 - 2025 |
| Vascular Biogenics Ltd. VBLT | Director | filed 2023 - 2023 |
| Entasis Therapeutics Holdings Inc. [ETTX] | Director | filed 2018 - 2022 |
| Unilife Corp UNIS | See Remarks | filed 2015 - 2017 |
| Incyte Corp INCY | Chief Financial Officer | filed 2006 - 2014 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.